CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

IN8bio Q3 net loss widens as R&D expenses rise

By Reuters News


Overview

  • US biopharma firm's Q3 net loss widened yr/yr as R&D expenses increased

  • Company appointed Oxana Polyakova as SVP of Research & Development


Result Drivers

  • PIPELINE DEVELOPMENT - Co continued preclinical development of INB-619 for oncology and autoimmune indications

  • LEADERSHIP CHANGE - Appointment of new SVP of R&D to accelerate γδ TCE pipeline


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$4.59 mln

Q3 Loss Per Basic Share

$0.24

Q3 Operating Expenses

$4.72 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for IN8bio, Inc. is $6.00, about 544.7% above its November 4 closing price of $0.93


Reuters Recommended Reads

  • Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs

  • Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

  • Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.